Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

NCT02714218 ·Status: COMPLETED ·Phase: PHASE3

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

NCT02731729 ·Status: COMPLETED ·Phase: PHASE2

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

NCT01844505 ·Status: COMPLETED ·Phase: PHASE3

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

NCT03732560 ·Status: COMPLETED

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

NCT02388906 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

NCT03329846 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

NCT03068455 ·Status: COMPLETED ·Phase: PHASE3

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162 ·Status: TERMINATED ·Phase: PHASE2

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

NCT03448497 ·Status: COMPLETED

TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma

NCT03293784 ·Status: COMPLETED ·Phase: PHASE1

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

NCT06566391 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

NCT02320058 ·Status: COMPLETED ·Phase: PHASE2

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy

NCT02990611 ·Status: COMPLETED

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

NCT03528408 ·Status: UNKNOWN ·Phase: PHASE2

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

NCT07091695 ·Status: COMPLETED

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

NCT00803374 ·Status: WITHDRAWN ·Phase: PHASE1

Long-term Data Collection for Subjects in MDX-010 Studies

NCT00928031 ·Status: COMPLETED

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

NCT02374242 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Cryoablation+Ipilimumab+Nivolumab in Melanoma

NCT05779423 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

NCT04495010 ·Status: WITHDRAWN ·Phase: PHASE2

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

NCT01515189 ·Status: COMPLETED ·Phase: PHASE3

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

NCT01654692 ·Status: COMPLETED ·Phase: PHASE2

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

NCT02978443 ·Status: TERMINATED ·Phase: PHASE2